Evotec Folds ProPharma Subsidiary into Services Division
Evotec said last week that ProPharma Limited, Evotec's Glasgow, Scotland-based formulation subsidiary, is now conducting its business under the Evotec brand.
ProPharma will be integrated into the Evotec Services Division over the coming months, Evotec said in a statement.
Evotec has been the majority shareholder in ProPharma since it was formed as a spin-out enterprise from the University of Strathclyde in Glasgow in 2000.
Evotec said the integration will combine its experience in pharmaceutical ingredient manufacture with ProPharma's expertise in pharmaceutical formulation development, further broadening Evotec's range of drug discovery services.
TNO, Mitsubishi Pharma Enter siRNA Target Validation Pact
Dutch biotech TNO and Mitsubishi Pharma of Japan have entered into a technology development collaboration for siRNA-based target validation studies, the companies said last week.
Under the terms of the agreement, TNO will use its siRNA knockdown technology and disease models to further characterize a set of Mitsubishi's proprietary disease targets.
Financial terms of the agreement were not disclosed.
Keck Awarded $4.88M Grant to 'Rewire' Yeast
The Keck Graduate Institute of Applied Life Sciences has been awarded a 5-year, $4.88 million grant from the National Science Foundation to investigate cellular function and determine whether or not cells can be re-engineered, KGI said last week.
KGI researchers will be using the funding made available through the NSF's Frontiers in Integrative Biological Research program to "rewire" the molecular machinery of S. cerevisiae yeast, predict the reaction of the cellular machinery to the rewiring, and compare it with direct experiments.
KGI said it believes that if functional modules in the cell can be rewired, it may be possible to "reengineer" cells for complex functions.